Dow Jones

53 055,91

0,29%

Germany 40

Inscrivez-vous gratuitement pour obtenir des cotations en temps réel, des graphiques interactifs, un flux d'options en direct et plus encore.

Accueil
Investir
Actions
Royaume-Uni
LSE
Sandoz Group AG (0SAN)
Sandoz Group AG (0SAN) Actualités

Sandoz Group AG (0SAN)

0,00

(0,00%)

Fermé 07 Juillet 5:30PM

Discussions et idées de trading en temps réel : négociez en toute confiance avec notre puissante plateforme.

Premium

European Stocks Decline, Extending Previous Session’s Losses: DAX, CAC, FTSE100

European equities moved lower on Wednesday, continuing the downward trend from the prior session after a report from the The Wall Street Journal...

DAX, CAC, FTSE100, European markets trade mixed as investors await a wave of central bank decisions

European equities delivered a mixed performance on Monday as traders positioned themselves ahead of a busy week packed with interest rate...

DAX, CAC, FTSE100, European Stocks Slip as AI Bubble Fears Weigh on Sentiment

European equity markets moved mostly lower on Monday, as renewed anxiety over a potential artificial-intelligence bubble and slowing global...

European markets mixed as U.S. extends tariff pause on China

European stocks posted another mixed performance on Tuesday after Washington extended its suspension of higher tariffs on Chinese goods until...

Sandoz launches renewable energy partnership to cover nearly 90% of electricity demand for European operations

Sandoz launches renewable energy partnership to cover nearly 90% of electricity demand for European operations MEDIA RELEASE Sandoz signs 10-year...

Sandoz delivers strong H1 2025 results, with accelerated sales growth in the second quarter

Sandoz delivers strong H1 2025 results, with accelerated sales growth in the second quarter Ad hoc announcement pursuant to art. 53 SIX Swiss...

Sandoz signs non-binding term sheet with Evotec SE to acquire its Just-Evotec Biologics in-house development and manufacturing capabilities in Toulouse, France

Sandoz signs non-binding term sheet with Evotec SE to acquire its Just-Evotec Biologics in-house development and manufacturing capabilities in...

Sandoz further asserts leadership in biosimilars, breaking ground on new Slovenia facility to expand European biosimilar hub and global market reach

Sandoz further asserts leadership in biosimilars, breaking ground on new Slovenia facility to expand European biosimilar hub and global market...

Sandoz launches first and only interchangeable denosumab biosimilars in US, providing new affordable treatment options for over 10 million patients[1]

Sandoz launches first and only interchangeable denosumab biosimilars in US, providing new affordable treatment options for over 10 million...

Sandoz launches Pyzchiva® autoinjector, first commercially available in Europe for ustekinumab biosimilars

Sandoz launches Pyzchiva® autoinjector, first commercially available in Europe for ustekinumab biosimilars MEDIA RELEASE Pyzchiva® first...

Sandoz reports Q1 2025 net sales in line with company expectations; full-year guidance confirmed

Sandoz reports Q1 2025 net sales in line with company expectations; full-year guidance confirmed Ad-hoc announcement pursuant to art. 53 SIX Swiss...

Sandoz enters global collaboration license agreement with Henlius to commercialize leading oncology therapy, ipilimumab, in multiple indications

Sandoz enters global collaboration license agreement with Henlius to commercialize leading oncology therapy, ipilimumab, in multiple indications...

Shareholders approve all resolutions proposed by Board of Directors at Annual General Meeting of Sandoz Group AG

Shareholders approve all resolutions proposed by Board of Directors at Annual General Meeting of Sandoz Group AG All proposals of Board of...

[Corrected] Sandoz files antitrust litigation against Amgen regarding patient access to etanercept biosimilar in the US

[Corrected] Sandoz files antitrust litigation against Amgen regarding patient access to etanercept biosimilar in the US Ad hoc announcement...

Sandoz files antitrust litigation against Amgen regarding patient access to etanercept biosimilar in the US

Sandoz files antitrust litigation against Amgen regarding patient access to etanercept biosimilar in the US Ad hoc announcement pursuant to art...

Forums

Afficher les forums

Aucune Discussion Trouvée

Ajouter une Discussion

DJ Islamic Market India ...

NASDAQ

ABNLGXX

Morgan Stanley Dual Dire...

Integrated Green Energy ...

NASDAQI

B5020PI

OMX Baltic Industrial Go...

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

Vous avez déjà un compte? Connexion

Vous n'avez pas de compte ? Inscription

En m'inscrivant, je confirme avoir lu, compris et accepté les Conditions générales d'ADVFN et j'affirme etre un investisseur privé.

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

Sandoz Group AG (0SAN)

Discussions et idées de trading en temps réel : négociez en toute confiance avec notre puissante plateforme.